Publications by authors named "Aixa E Soyano-Muller"
Background: Combination CDK4/6 inhibitor and endocrine therapy has been shown to significantly improve progression-free survival (PFS) in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (mBC). The aim of this retrospective study was to evaluate the real-world benefit of first-line combination therapy in this cohort and to correlate treatment efficacy with neutropenia, a common toxicity of CDK4/6 inhibitors.
Methods: This study included HR-positive, HER2-negative advanced or mBC patients who were treated with palbociclib plus endocrine therapy, mainly letrozole, between 1 January 2015 and 1 March 2018.
Article Synopsis
- Increasing data indicate that preexisting immune responses and neoantigen levels are crucial for how well patients respond to immune checkpoint inhibitors (ICIs), with tumor mutational burden (TMB) being a notable biomarker in lung cancer and melanoma.
- In a case study, a patient with HER2-negative breast cancer and high TMB achieved a lasting complete response to ICIs, even with low levels of tumor-infiltrating lymphocytes and PD-L1 negativity, suggesting a unique treatment outcome despite typically unfavorable indicators.
- Analysis of a large cohort revealed that many TMB-high tumors were PD-L1-negative, showing that TMB can still play a valuable role in predicting ICI responses in breast cancer, challenging the notion of relying
Purpose: Young age has been shown to be an independent predictor of poor outcome in breast cancer. In HER2-positive breast cancer, the effects of aging remain largely unknown.
Experimental Design: A total of 4,547 patients were included [3,132 from North Central Cancer Treatment Group (NCCTG) N9831 and 1,415 from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31].